lactate dehydrogenase A like 6D, pseudogeneGenealiases: []
Q-omics provides the consensus-scored LDHAL6DP profile across patient tissues and cancer cell-line models. LDHAL6DP expression is associated with patient survival in 8 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, LDHAL6DP is differentially expressed in 1, with the highest sampling consensus in LIHC. Additionally, LDHAL6DP RNA expression shows 15,839 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight READ, LIHC, and GBM as cancer lineages where LDHAL6DP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LDHAL6DP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LDHAL6DP survival associations across molecular data types. LDHAL6DP RNA expression shows survival associations in the most cancer types (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LDHAL6DP RNA expression–survival associations across cancer types. High LDHAL6DP expression shows unfavorable associations in READ, SKCM, KIRC, THCA, UCEC and LUAD. The READ Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify READ as the clearest survival context for LDHAL6DP RNA expression.
This table summarizes LDHAL6DP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for LDHAL6DP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LDHAL6DP shows lower tumor expression in LIHC. The LIHC box plot shows higher LDHAL6DP RNA expression in normal versus tumor tissue (log2 FC = −0.022, t-test p = .030).
This table shows molecular features associated with LDHAL6DP in patient tissues and cancer cell lines. In patient samples, LDHAL6DP shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
